Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAPRI-3 GOIM: Cetuximab Beyond First-Line Progression in mCRC
NCT07389265Phase 3Recruiting
- Sponsor
- University of Campania Luigi Vanvitelli
- Start
- Oct 2025
- Primary completion
- Oct 2030
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 3 trial of KL-140 in metastatic colorectal cancer (mCRC), sponsored by University of Campania Luigi Vanvitelli. Started Oct 2025; status: recruiting.
02
Drugs
KL-140
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT07389265.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07389265.